Annovis stock swells after Phase III Parkinson's subgroup ...

Annovis Bio's share price surged 100% after positive Phase III trial results for buntanetap in Parkinson's disease, showing improved cognition. The trial involved 523 patients, with significant improvements in MDS-UPDRS scores for those diagnosed over three years ago and with PIGD. Despite a setback in Alzheimer's trial, Annovis plans a Phase III trial.